In vitro and in vivo activity of 2,4-diamino-6-(2-(3,4-dichlorophenyl)acetamido) quinazoline against Cryptococcus neoformans.
The minimum inhibitory concentration of quinazoline derivative was determined by the tube dilution method for Cryptococcus neoformans, strain 184. The effect of this chemical agent on macromolecular metabolism indicated an inhibition of incorporations of labeled precursors into RNA and protein of C. neoformans. A mouse model infection with C. neoformans was established. Following this, the animals were given ip or oral doses of different concentrations of the experimental drug. Infected mice responded to ip administration of the drug in that the percentage of surviving mice increased progressively with increasing drug dosage. The curing dose 50 (CD50) was determined, based on the isolation of C. neoformans from organs of animals during or at the termination of the experiments.
D000935:Antifungal Agents; D003453:Cryptococcosis / Q000188:drug therapy; D003454:Cryptococcus; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000378:metabolism; D005656:Fungal Proteins / Q000096:biosynthesis; D011799:Quinazolines / Q000494:pharmacology* / Q000627:therapeutic use; D012313:RNA / Q000096:biosynthesis
D000935:Antifungal Agents; D005656:Fungal Proteins; D011799:Quinazolines; D012313:RNA